Kura Oncology Stock Performance

KURA
 Stock
  

USD 13.07  0.59  4.32%   

The company secures a Beta (Market Risk) of 0.5699, which conveys possible diversification benefits within a given portfolio. Let's try to break down what Kura Oncology's beta means in this case. As returns on the market increase, Kura Oncology returns are expected to increase less than the market. However, during the bear market, the loss on holding Kura Oncology will be expected to be smaller as well. Even though it is essential to pay attention to Kura Oncology price patterns, it is always good to be careful when utilizing equity historical price patterns. Our philosophy towards estimating any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Kura Oncology exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Kura Oncology has an expected return of -0.52%. Please be advised to verify Kura Oncology semi variance, and the relationship between the maximum drawdown and accumulation distribution to decide if Kura Oncology performance from the past will be repeated at some point in the near future.
  
Kura Oncology Performance
0 of 100
Over the last 90 days Kura Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in November 2022. The current disturbance may also be a sign of long term up-swing for the company investors. ...more

Kura Oncology Price Channel

Quick Ratio27.08
Fifty Two Week Low10.41
Target High Price56.00
Fifty Two Week High19.93
Target Low Price22.00

Kura Oncology Relative Risk vs. Return Landscape

If you would invest  1,888  in Kura Oncology on July 6, 2022 and sell it today you would lose (581.00)  from holding Kura Oncology or give up 30.77% of portfolio value over 90 days. Kura Oncology is currently does not generate positive expected returns and assumes 3.6214% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Kura Oncology, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Daily Expected Return (%)  
       Risk (%)  
Given the investment horizon of 90 days Kura Oncology is expected to under-perform the market. In addition to that, the company is 3.01 times more volatile than its market benchmark. It trades about -0.14 of its total potential returns per unit of risk. The DOW is currently generating roughly -0.06 per unit of volatility.

Kura Oncology Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Kura Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kura Oncology, and traders can use it to determine the average amount a Kura Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.1429

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsKURA
Estimated Market Risk
 3.62
  actual daily
 
 31 %
of total potential
 
3131
Expected Return
 -0.52
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 -0.14
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Kura Oncology is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kura Oncology by adding it to a well-diversified portfolio.

About Kura Oncology Performance

To evaluate Kura Oncology Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Kura Oncology generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Kura Oncology Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Kura Oncology market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Kura Oncology's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 117 people.

Things to note about Kura Oncology

Checking the ongoing alerts about Kura Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kura Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Kura Oncology Alerts

Equity Alerts and Improvement Suggestions

Kura Oncology generated a negative expected return over the last 90 days
Kura Oncology has high historical volatility and very poor performance
Net Loss for the year was (132.22 M) with profit before overhead, payroll, taxes, and interest of 0.
Kura Oncology currently holds about 480.08 M in cash with (108.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.2.
Latest headline from www.marketscreener.com: KURA ONCOLOGY, INC. Change in Directors or Principal Officers - Marketscreener.com
Please see Correlation Analysis. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for analysis

When running Kura Oncology price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine Kura Oncology value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.